Latest From Chiasma Inc.
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Chiasma has bounced back from a 2016 CRL for Mycapssa with a new SPA-agreed Phase III trial meeting all its primary and secondary endpoints. The product is positioned to be the first oral treatment for acromegaly.
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
Biopharma sponsors should start with information that needs to be disclosed to satisfy SEC rules and understand how a press release will be used to avoid running afoul of agency regulations, industry exec says; company contracts with investigators also should set limits on what they can say about an unapproved drug.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Chiasma (Israel) Ltd.
- North America
- Parent & Subsidiaries
- Chiasma Inc.
- Senior Management
Raj Kannan, CEO
Asi Haviv, VP, Clin. Dev.
Dana Gelbaum, VP, Global Mktg. & Corp. Dev.
Mark J Fitzpatrick, Pres.
Drew Enamait, VP, Fin. & Admin.
- Contact Info
Phone: (972)(844) 304-2462
460 Totten Pond Rd., Ste. 530
Waltham, MA 02451
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.